Using Modern Imaging Technology

Learn More

With new, proprietary drug formulations

Learn More

To precisely treat late stage and metastatic cancer

Learn More

and to stimulate a natural, adaptive immune response.

Learn More

Intensity Therapeutics is creating a new, highly effective cancer treatment - in situ vaccination.

Learn More

Clinical Trials

 

NT230-6 is being evaluated in a human clinical trial, IT-01. The study is entitled, A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers. The trial aims to enroll patients with different types advanced solid tumor malignancies in a multicycle dosing regimen. Study IT-01 plans to include a cohort combining INT230-6 with an anti-PD-1 antibody. Currently the study is recruiting patients in the U.S. at the University of Southern California (USC) and in Canada at the University Health Network (UHN) in Toronto. The principal investigator at USC is Dr. Anthony El-Khoueiry; the principal investigator at UHN is Dr. Lillian Siu. The study’s primary objective is to assess the safety and tolerability of multiple intratumoral doses of INT230-6. Secondary assessments are to understand preliminary efficacy of INT230-6. The study will characterize the pharmacokinetic profile of multiple doses of INT230-6 components. Exploratory analysis will characterize patient outcome, as well as evaluate various tumor and anti-tumor immune response biomarkers that may correlate with response. Data will be used to assess the progression free and overall survival in subjects receiving INT230-6. Further information can be found at www.clinicaltrials.gov (NCT#03058289).

Contact Us


Intensity Therapeutics, Inc.
61 Wilton Road, 3rd Floor
Westport, CT 06880


Tel. (203) 221-7377
Fax (203) 664-1051


info@intensitytherapeutics.com

 

Who we are


Intensity Therapeutics is a clinical development stage company.  We are seeking partnerships/investors interested in advancing the company’s anti-cancer platform technology and lead product INT230-6.

 

Click here for inquiries

News